Chemical Nameinotersen
Dosage Form Injection (subcutaneous; 284 mg)
Drug ClassOligonucleotides
SystemCardiovascular, Musculoskeletal, Skin, Blood, Urinary, Cardiovascular, Nervous
CompanyAkcea Therapeutics
Approval Year2018


  • To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Last updated on 3/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tegsedi (Inotersen) Prescribing Information 2018Akcea Therapeutics, Boston, MA